Kirbex 75 Mg/ 150 Mg/ 300 Mg Tablets 75 mg/ 150 mg/ 300 mg TABLETS
PDF Leaflet Revision Date: 23 February 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of essential hypertension and diabetic nephropathy in Type 2 diabetes.
Dosage (summary)
Initial: 150 mg once daily; may increase to 300 mg if needed.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Discontinue if pregnancy occurs; not established for safety in lactation.
Key Drug Interactions
- Potassium-sparing diuretics
- Lithium
- NSAIDs
Contraindications
- Hypersensitivity to irbesartan
- History of angioedema
- Severe renal impairment
- Bilateral renal artery stenosis
Common side effects
- Dizziness
- Fatigue
- Nausea
- Orthostatic hypotension
Counselling Points
- Monitor blood pressure regularly
- Avoid potassium supplements
- Report any signs of angioedema
Serious warnings
- Risk of hypotension in volume-depleted patients
- Hyperkalaemia
- Dual blockade of RAAS increases risks
Important Disclaimer
The Kirbex 75 Mg/ 150 Mg/ 300 Mg Tablets 75 mg/ 150 mg/ 300 mg TABLETS professional information leaflet below is the property of Aurogen South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
